Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 USD | +3.12% | -0.83% | -11.48% |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Apr. 04 | Traws Pharma, Inc. Announces Chief Executive Office Changes | CI |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.48% | 13.49M | - | ||
+0.17% | 42.86B | B | ||
+10.92% | 42.74B | B- | ||
+44.30% | 41.36B | A | ||
-6.20% | 27.68B | C | ||
+5.23% | 25.15B | B- | ||
-24.79% | 18.63B | B | ||
+26.69% | 12.37B | C+ | ||
-3.13% | 11.92B | C+ | ||
+6.57% | 11.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TRAW Stock
- Ratings Traws Pharma, Inc.